Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-15

Clinical Trial Update: A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD [Phase 2]

View source ↗

Summary

A biomarker-guided, randomized, placebo-controlled Phase 2 trial evaluating Liafensine for treatment-resistant depression has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Liafensine (Liafensine)

Snippet

Sponsor: Denovo Biopharma LLC | Conditions: Treatment Resistant Depression | Phase 2 | Status: COMPLETED | Results posted: 2025-05-15